HSG provides antitumor efficacy on hepatocellular carcinoma both in vitro and in vivo

被引:28
作者
Wang, Weilin [1 ]
Zhu, Feng [1 ]
Wang, Shuqian [1 ]
Wei, Jianfeng [1 ]
Jia, Changku [1 ]
Zhang, Yuanbiao [1 ]
Zhou, Lin [1 ]
Xie, Haiyang [1 ]
Zheng, Shusen [1 ]
机构
[1] Zhejiang Univ, Dept Hepatobiliary & Pancreat Surg,Affiliated Hos, Key Lab Organ Transplantat,Minst Publ Hlth,Med Co, Key Lab Combined Multiorgan Transplantat,Sch Med, Hangzhou 310003, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
hyperplasia suppressor gene; antitumor; gene therapy; cell cycle; hepatocellular carcinoma; MITOCHONDRIAL FUSION; TUMOR-SUPPRESSOR; GENE; MECHANISMS; MFN2; P27;
D O I
10.3892/or_00000844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hyperplasia suppressor gene (HSG) is a novel gene that markedly suppresses the mitogenetic stimuli or injury mediated by vascular smooth muscle cell proliferation. Herein we provide experimental evidence to show that HSG can also play a key role in tumor proliferation. Downregulation of HSG protein in hepatocellular carcinoma tissues compared to adjacent tissues. Overexpression of HSG suppressed the growth of liver cancer cell lines, resulted in cell cycle arrest in the G0/G1 phase, increased expression of the cyclin dependent kinase inhibitors (CKIs), and reduced expression of proliferating cell nuclear antigen (PCNA). It also showed that adenovirus-mediated HSG overexpression induced apoptosis. Up-regulation of HSG by adenovirus also significantly suppressed the growth of subcutaneous tumors in nude mice both ex vivo and in vivo. Collectively, our data suggest that HSG is a potential therapy for tumors and possibly other proliferative diseases as well and it has antitumor efficacy on hepatocellular carcinoma by using adenovirus vectors, which may be a new therapeutic target for liver cancer prevention.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 26 条
  • [1] ALCOCEBA RH, 2006, WORLD J GASTROENTERO, V12, P6085
  • [2] The quest for the 1p36 tumor suppressor
    Bagchi, Anindya
    Mills, Alea A.
    [J]. CANCER RESEARCH, 2008, 68 (08) : 2551 - 2556
  • [3] Management of hepatoceullular carcinoma
    Bruix, J
    Sherman, M
    [J]. HEPATOLOGY, 2005, 42 (05) : 1208 - 1236
  • [4] Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development
    Chen, HC
    Detmer, SA
    Ewald, AJ
    Griffin, EE
    Fraser, SE
    Chan, DC
    [J]. JOURNAL OF CELL BIOLOGY, 2003, 160 (02) : 189 - 200
  • [5] Dysregulation of HSG triggers vascular proliferative disorders
    Chen, KH
    Guo, XM
    Ma, DL
    Guo, YH
    Li, QA
    Yang, DM
    Li, PF
    Qiu, XY
    Wen, SJ
    Xiao, RP
    Tang, JA
    [J]. NATURE CELL BIOLOGY, 2004, 6 (09) : 872 - U8
  • [6] Mechanisms of human hepatocarcinogenesis
    Coleman, WB
    [J]. CURRENT MOLECULAR MEDICINE, 2003, 3 (06) : 573 - 588
  • [7] Genetic mechanisms of hepatocarcinogenesis
    Feitelson, MA
    Sun, B
    Tufan, NLS
    Liu, J
    Pan, JB
    Lian, ZR
    [J]. ONCOGENE, 2002, 21 (16) : 2593 - 2604
  • [8] Fiorentino M, 2000, CLIN CANCER RES, V6, P3966
  • [9] In human hepatocellular carcinoma in cirrhosis, proliferating cell nuclear antigen (PCNA) is involved in cell proliferation and cooperates with P21 in DNA repair
    Gramantieri, L
    Trerè, D
    Chieco, P
    Lacchini, M
    Giovannini, C
    Piscaglia, F
    Cavallari, A
    Bolondi, L
    [J]. JOURNAL OF HEPATOLOGY, 2003, 39 (06) : 997 - 1003
  • [10] Mitofusin 2 triggers vascular smooth muscle cell apoptosis via mitochondrial death pathway
    Guo, Xiaomei
    Chen, Kuang-Hueih
    Guo, Yanhong
    Liao, Hua
    Tang, Jian
    Xiao, Rui-Ping
    [J]. CIRCULATION RESEARCH, 2007, 101 (11) : 1113 - 1122